Disease Atlas / Disease detail
An educational overview summarizing the definition, symptoms, diagnosis, and treatment of heroin dependence, along with the interpretation of evidence.
heroin dependence · Heroin addiction
Start with the essentials, then explore the patient and research views.
Public revision · 199e2e528cdf
A structured guide for understanding the disease and preparing for clinical conversations.
Heroin dependence is a chronic use disorder characterized by the repeated use of heroin, an illegal opioid derived from morphine, despite harmful consequences.
Notably, intense euphoria or a 'rush' may be followed by drowsiness, respiratory depression, dry mouth, flushing, pruritus (itching), nausea, and vomiting.
Heroin carries a high risk of dependence due to administration routes that allow it to reach the brain quickly and its strong rewarding effects; the presence of adulterants or co-use with other drugs or alcohol can increase the risk of overdose.
Repeated use can cause adaptations in the reward circuitry and stress/impulse control systems, which may promote tolerance, craving, decreased control, and withdrawal.
Individual risk varies depending on the route of administration, amount and frequency of use, changes in tolerance, comorbid mental health conditions, use of other depressant substances, and exposure to injection-related infections.
Long-term use can lead to tolerance, physical dependence, and withdrawal; upon cessation, restlessness, muscle/bone pain, diarrhea, vomiting, chills, and goosebumps may occur; injection drug users also face risks of HIV, hepatitis, skin/bloodstream/heart infections, and abscesses.
Diagnosis is made by synthesizing clinical interviews and physical/mental health assessments, encompassing patterns of use, difficulty in control, cravings, functional impairment, hazardous use, and withdrawal/tolerance.
A substance use disorder cannot be determined solely on the basis of physical dependence or withdrawal, and toxicology test results only provide supplementary evidence of recent exposure; they do not independently confirm the severity of the disorder or recovery status.
Management includes overdose prevention and emergency response, treatment of withdrawal, cravings, and substance use disorders, as well as integrated assessment and support for infections, mental health, and social issues.
The current major direction of treatment is the concurrent application of pharmacotherapy addressing withdrawal and opioid effects and behavioral therapy, tailored to the patient's situation; a combination of pharmacotherapy and behavioral therapy may be helpful.
The Tele-Harm Reduction study (NCT05208697) is registered on ClinicalTrials.gov with a status of completed; however, since the results have not been posted, the fact of registration alone cannot be used to determine efficacy, safety, or whether it constitutes standard treatment.
In clinical practice, one can also verify the timing, amount, and route of use, recent discontinuation, history of withdrawal or overdose, use of other drugs or alcohol, possibility of pregnancy, infection or mental health issues, naloxone accessibility, and desired treatment goals.
This material is for educational purposes and does not serve as a substitute for individual diagnosis or treatment.
A trial registry status does not establish efficacy or regulatory approval.
ClinicalTrials.gov · TRIAL REGISTRY
Europe PMC · BIBLIOGRAPHIC RECORD
MedlinePlus · GOVERNMENT SUMMARY
MONDO · ONTOLOGY